Liver involvement in human immunodeficiency virus infection

被引:8
作者
Puri P. [1 ]
Kumar S. [1 ]
机构
[1] Department of Internal Medicine, Armed Forces Medical College, Pune
关键词
Hepatotoxicity; Highly effective anti-retroviral therapy (HAART); Human immunodeficiency virus (HIV); Liver disease;
D O I
10.1007/s12664-016-0666-8
中图分类号
学科分类号
摘要
The advances in management of patients with acquired immunodeficiency syndrome (AIDS) with highly effective anti-retroviral therapy (HAART) have resulted in increased longevity of patients with human immunodeficiency virus (HIV) infection. AIDS-related illnesses now account for less than 50 % of the deaths, and liver diseases have emerged as the leading cause of death in patients with HIV infection. Chronic viral hepatitis, drug-related hepatotoxicity, non-alcoholic fatty liver disease, and opportunistic infections are the common liver diseases that are seen in HIV-infected individuals. Because of the shared routes of transmission, co-infections with hepatitis B virus (HBV) and hepatitis C virus (HCV) are very common in HIV-infected persons. Hepatitis C is the most common viral hepatitis seen in HIV-infected patients. With the availability of directly acting agents, treatment outcome of HCV is comparable to that seen in non HIV-infected patients. Careful monitoring is required for drug interactions and drug-induced hepatotoxicity and modification of drugs should be done where necessary. The results of liver transplantation in select HIV-infected patients can be comparable with those of HIV-negative patients. © 2016, Indian Society of Gastroenterology.
引用
收藏
页码:260 / 273
页数:13
相关论文
共 136 条
  • [1] Ministry of Health and Family Welfare, (2015)
  • [2] Weber R., Sabin C.A., Friis Muller N., Et al., Liver related deaths in the Human immunodeficiency virus: D: A: D study, Arch Intern Med, 166, pp. 1632-1641, (2006)
  • [3] Bica I., McGovern B., Dhar R., Et al., Increasing mortality due to end stage liver disease in patients with Human immunodeficiency virus infection, Clin Infect Dis, 32, pp. 492-497, (2001)
  • [4] Weber R., Ruppik M., Rickenbach M., Et al., Decreasing mortality and changing patterns of causes of death in the Swiss HIV cohort study, HIV Medicine, 14, pp. 195-207, (2013)
  • [5] Whiteside Y.O., Selik R., An Q., Et al., Comparisons of rates of death having any death certificate mention of Heart, Kidney or Liver disease among persons diagnosed with HIV infection with those in general US population, 2009-2011, Open AIDS J, 9, pp. 14-22, (2015)
  • [6] Kovari H., Sabin C.A., Ledergerber B., Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study, Clin Infect Dis, 56, pp. 870-879, (2013)
  • [7] Belloso W.H., Orellana L.C., Grinsztejn B., Et al., Analysis of serious non AIDS events among HIV infected adults at Latin American sites, HIV Med, 11, pp. 554-564, (2010)
  • [8] Kovari H., Ledergerber B., Battegay M., Et al., Incidence and risk factors for chronic elevation of Alanine aminotransferase levels in HIV infected persons without hepatitis b or c virus coinfection, Clin Infect Dis, 50, pp. 502-511, (2010)
  • [9] Crum-Ciaflone N., Collins G., Medina S., Et al., Prevalence and factors associated with liver test abnormalities among human immunodeficiency virus infected persons, Clin Gastroenterol Hepatol, 8, pp. 183-191, (2010)
  • [10] DallaPiazza M., Amorosa V.K., Localio R., Kostman J.R., Lo Re V., Prevalence and risk factors for significant liver fibrosis among HIV monoinfected patients, BMC Infect Dis, 10, (2010)